Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-08 |
2024-06 |
-53.6 |
N/A |
N/A |
N/A |
2024-05-13 |
2024-03 |
-53.6 |
-3.28 |
50.32 |
93.88% |
2024-03-22 |
2023-12 |
-8.08 |
-1.76 |
6.32 |
78.22% |
2023-11-09 |
2023-09 |
-8.56 |
-5.2 |
3.36 |
39.25% |
2023-08-10 |
2023-06 |
-10.08 |
-11.44 |
-1.36 |
-13.49% |
2023-05-11 |
2023-03 |
-15.84 |
-17.84 |
-2 |
-12.63% |
Date |
Name |
Relation |
Quantity |
Description |
2023-02-12 |
ARTHUR DAVID J |
Chief Executive Officer |
49.14K |
Stock Award(Grant) |
2023-01-02 |
BURLESON TESS |
Director |
2.72K |
Stock Award(Grant) |
2023-01-02 |
HANISH ARNOLD C |
Director |
3.29K |
Stock Award(Grant) |
2020-02-17 |
JORDAN SCOTT |
Officer |
31.61K |
Purchase |
2023-01-02 |
LAMMERS PAUL I |
Director |
1.72K |
Stock Award(Grant) |
2023-01-02 |
LIEBER JONATHAN I |
Director |
2.94K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Armistice Capital, LLC |
109.64K |
163.36K |
3.01% |
2023-06-29 |
Horizon Kinetics Asset Management LLC |
32.40K |
48.28K |
0.89% |
2023-06-29 |
Renaissance Technologies, LLC |
20.54K |
30.61K |
0.56% |
2023-06-29 |
Geode Capital Management, LLC |
16.52K |
24.62K |
0.45% |
2023-06-29 |
Vanguard Group Inc |
14.96K |
22.29K |
0.41% |
2023-06-29 |
Susquehanna International Group, LLP |
10.46K |
15.59K |
0.29% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Listed Funds Tr-Horizon Kinetics Medical ETF |
32.40K |
48.28K |
0.89% |
2023-06-29 |
Vanguard Extended Market Index Fund |
14.26K |
21.25K |
0.39% |
2023-05-30 |
Fidelity Extended Market Index Fund |
8.34K |
11.77K |
0.23% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
2.47K |
3.48K |
0.07% |
2023-05-30 |
Fidelity Total Market Index Fund |
2.57K |
3.63K |
0.07% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
1.40K |
1.98K |
0.04% |
Split |
Date |
1 : 8 |
2024-06-17 |
1 : 25 |
2022-10-17 |
1 : 25 |
2019-07-22 |